DSGN EBITDA | Design Therapeutics, Inc.

Design Therapeutics, Inc. (DSGN) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$22.18M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$19.71M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$19.31M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$21.57M; Depreciation and amortization (m).

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$22.18M	(m)	(m)	(m)	$21.00K*	-$15.52M*	(m)	$16.39M	(m)	(m)
2026-03-31	Reported	(m)	-$19.71M	(m)	(m)	(m)	$0.00	-$16.43M	(m)	$14.38M	(m)	(m)
2025-09-30	Reported	(m)	-$19.31M	(m)	(m)	(m)	$0.00*	-$11.16M*	(m)	$14.59M	(m)	(m)
2025-06-30	Reported	(m)	-$21.57M	(m)	(m)	(m)	$87.00K*	-$14.44M*	(m)	$15.74M	(m)	(m)
2025-03-31	Reported	(m)	-$20.42M	(m)	(m)	(m)	$72.00K	-$16.79M	(m)	$15.38M	(m)	(m)
2024-09-30	Reported	(m)	-$16.25M	(m)	(m)	(m)	-$16.00K*	-$9.55M*	(m)	$11.88M	(m)	(m)
2024-06-30	Reported	(m)	-$15.04M	(m)	(m)	(m)	$161.00K*	-$11.26M*	(m)	$10.52M	(m)	(m)
2024-03-31	Reported	(m)	-$14.40M	(m)	(m)	(m)	$195.00K	-$12.44M	(m)	$9.80M	(m)	(m)
2023-09-30	Reported	(m)	-$18.82M	(m)	(m)	(m)	$53.00K*	-$14.53M*	(m)	$13.26M	(m)	(m)
2023-06-30	Reported	(m)	-$22.60M	(m)	(m)	(m)	$89.00K*	-$13.80M*	(m)	$17.06M	(m)	(m)
2023-03-31	Reported	(m)	-$21.65M	(m)	(m)	(m)	$87.00K	-$17.42M	(m)	$15.73M	(m)	(m)
2022-09-30	Reported	(m)	-$19.19M	(m)	(m)	(m)	$310.00K*	-$13.90M*	(m)	$14.30M	(m)	(m)
2022-06-30	Reported	(m)	-$15.64M	(m)	(m)	(m)	$244.00K*	-$10.50M*	(m)	$11.29M	(m)	(m)
2022-03-31	Reported	(m)	-$13.37M	(m)	(m)	(m)	$76.00K	-$11.83M	(m)	$8.76M	(m)	(m)
2021-09-30	Reported	(m)	-$11.34M	(m)	(m)	(m)	$968.00K*	-$8.16M*	(m)	$8.54M	(m)	(m)
2021-06-30	Reported	(m)	-$7.69M	(m)	(m)	(m)	$183.00K*	-$8.29M*	(m)	$5.03M	(m)	(m)
2021-03-31	Reported	(m)	-$5.68M	(m)	(m)	(m)	$33.00K	-$3.70M	(m)	$3.88M	(m)	(m)
2020-09-30	Reported	(m)	-$2.38M	(m)	$20.00K	(m)	(m)	-$1.86M*	(m)	$1.91M	(m)	(m)
2020-06-30	Reported	(m)	-$1.46M	(m)	$31.00K	(m)	(m)	-$1.31M*	(m)	$1.06M	(m)	(m)
2020-03-31	Reported	(m)	-$623.00K	(m)	$142.00K	(m)	(m)	-$2.66M	(m)	$377.00K	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$79.47M	(m)	(m)	(m)	$193.00K	-$54.36M	(m)	$59.13M	(m)	$0.00
2024-12-31	Reported	(m)	-$62.38M	(m)	(m)	(m)	$340.00K	-$43.10M	(m)	$44.35M	(m)	$0.00
2023-12-31	Reported	(m)	-$78.19M	(m)	(m)	(m)	$256.00K	-$58.56M	(m)	$57.06M	(m)	(m)
2022-12-31	Reported	(m)	-$67.59M	(m)	(m)	(m)	$918.00K	-$51.32M	(m)	$48.61M	(m)	(m)
2021-12-31	Reported	(m)	-$35.83M	(m)	(m)	(m)	$1.54M	-$29.38M	(m)	$24.78M	(m)	(m)
2020-12-31	Reported	(m)	-$8.33M	(m)	$226.00K	(m)	$76.00K	-$8.67M	(m)	$6.06M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Wave Life Sciences, Inc. (WVE)		$0.780B	-5.56
Faeth Therapeutics, Inc. (FTH)	United States	$0.750B
Olema Pharmaceuticals, Inc. (OLMA)	United States	$0.790B	-5.35
Aclaris Therapeutics, Inc. (ACRS)	United States	$0.792B	-9.78
COLLEGIUM PHARMACEUTICAL, INC (COLL)	United States	$0.737B	24.57
GERON CORP (GERN)	United States	$0.803B	-12.14
GYRE THERAPEUTICS, INC. (GYRE)	United States	$0.818B	-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)	United States	$0.823B	-17.48
Verastem, Inc. (VSTM)	United States	$0.706B	-1.71
Nuvectis Pharma, Inc. (NVCT)	United States	$0.705B	-17.53